Woodrow Anderson Purchases 1,500 Shares of Indivior (NASDAQ:INDV) Stock

Indivior PLC (NASDAQ:INDV) CAO Woodrow Anderson acquired 1,500 shares of the company’s stock in a transaction dated Wednesday, August 5th. The stock was acquired at an average cost of $36.28 per share, for a total transaction of $54,420.00. Following the completion of the acquisition, the chief accounting officer directly owned 26,138 shares in the company, valued at approximately $948,286.64. The trade was a 6.09% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink.

Indivior Stock Performance

Shares of INDV traded up $2.23 during trading hours on Wednesday, hitting $38.73. The stock had a trading volume of 4,275,206 shares, compared to its average volume of 2,220,754. The firm has a market capitalization of $4.72 billion, a price-to-earnings ratio of 19.86 and a beta of 0.86. The firm has a 50-day moving average price of $39.15 and a 200 day moving average price of $35.53. Indivior PLC has a fifty-two week low of $21.48 and a fifty-two week high of $42.81.

Indivior (NASDAQ:INDV) last announced its earnings results on Tuesday, June 30th. The company reported $5.75 earnings per share for the quarter. Indivior had a negative return on equity of 310.69% and a net margin of 26.65%.The business had revenue of $343.00 million during the quarter. As a group, analysts predict that Indivior PLC will post 4.05 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on INDV. Barclays decreased their price target on shares of Indivior from $46.00 to $43.00 and set an “overweight” rating for the company in a research note on Wednesday. Craig Hallum reaffirmed a “buy” rating and set a $53.00 price objective on shares of Indivior in a report on Tuesday. Weiss Ratings upgraded Indivior from a “hold (c)” rating to a “hold (c+)” rating in a report on Friday, July 24th. Finally, Zacks Research downgraded shares of Indivior from a “strong-buy” rating to a “hold” rating in a research note on Monday, June 29th. Five investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $45.17.

Institutional Investors Weigh In On Indivior

Several large investors have recently modified their holdings of the stock. Caitong International Asset Management Co. Ltd grew its position in Indivior by 72.7% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 1,093 shares of the company’s stock worth $39,000 after purchasing an additional 460 shares in the last quarter. VIRGINIA RETIREMENT SYSTEMS ET Al increased its stake in Indivior by 3.4% in the fourth quarter. VIRGINIA RETIREMENT SYSTEMS ET Al now owns 21,200 shares of the company’s stock valued at $761,000 after acquiring an additional 700 shares during the period. Blue Trust Inc. increased its holdings in Indivior by 17.8% during the 4th quarter. Blue Trust Inc. now owns 4,859 shares of the company’s stock valued at $176,000 after purchasing an additional 733 shares in the last quarter. Harbor Capital Advisors Inc. boosted its stake in Indivior by 309.9% in the fourth quarter. Harbor Capital Advisors Inc. now owns 1,033 shares of the company’s stock valued at $37,000 after acquiring an additional 781 shares during the last quarter. Finally, Salomon & Ludwin LLC acquired a new stake in Indivior in the fourth quarter worth $30,000. 60.33% of the stock is owned by institutional investors.

Indivior Company Profile

Indivior plc is a specialty pharmaceutical company dedicated to developing and delivering treatments for addiction and related mental health disorders. The company’s portfolio centers on therapies designed to support individuals dealing with opioid dependence, alcohol use disorder and other behavioral health challenges. Its lead products include Suboxone® (buprenorphine and naloxone) sublingual film and Sublocade® (extended-release buprenorphine) injection, both of which are approved in multiple markets to aid in opioid use disorder management.

Indivior was established in 2014 through a demerger from the pharmaceuticals division of Reckitt Benckiser Group plc, inheriting decades of research and commercial expertise in addiction medicine.